Astellas Pharma (JP:4503) has released an update.
Astellas Pharma has announced that China’s National Medical Products Administration has approved PADCEVTM for the treatment of locally advanced or metastatic urothelial cancer following prior platinum-based chemotherapy and PD-1/L1 inhibitors. The approval is supported by the positive results from the global EV-301 trial and the China EV-203 trials, showing significant improvements in overall survival and objective response rates. This marks an important development in providing new treatment options for patients suffering from this aggressive form of cancer in China.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.